Cost of Care for Juvenile Idiopathic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01469897
Recruitment Status : Completed
First Posted : November 10, 2011
Last Update Posted : January 17, 2018
Information provided by (Responsible Party):
Andrew Zeft, The Cleveland Clinic

Brief Summary:
This project seeks to collect data on healthcare utilization and expenditure rates in Juvenile Idiopathic Arthritis (JIA) patients from across the US, correlate these costs with disease activity and outcome measures and determine methods by which to reduce the economic impact while improving outcomes.

Condition or disease
Juvenile Idiopathic Arthritis

Detailed Description:


The specific aims of this registry protocol are:

  • To create and maintain a secure online database of patients with JIA
  • To collect data elements related to cost of care in patients with JIA
  • Compare standard outcome and disease activity measures to health care expenditures in JIA
  • To determine methods by which to reduce costs while improving outcomes and quality of care

The study plans to enroll 300 or more subjects from 3 medical centers in the US over a 24 month period. Subjects in the study are patients with Juvenile Idiopathic Arthritis.

Enrollment into the protocol will include key demographic and clinical data including, medication exposures, disease severity, and function including disease-specific data elements; and estimates of health care service utilization and health care expenditures. Data will be collected once per subject within the context of a standard of care visit.

Study Type : Observational
Actual Enrollment : 165 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cost of Care for Juvenile Idiopathic Arthritis
Study Start Date : January 2012
Actual Primary Completion Date : December 2014
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Direct and indirect costs [ Time Frame: 6 months prior to enrollment ]
    Patient's history will be reviewed for the prior 6 months to enrollment for expenses incurred related to JIA and it's treatment. This will be done through chart review and questionnaires completed by the patient/parent.

Secondary Outcome Measures :
  1. Health related quality of life questionnaires [ Time Frame: Day 1 ]
    Self reported questionnaires will be completed by parent.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children, adolescents, and young adults with JIA within Cleveland Clinic Health System and at several other participating study sites.

Inclusion Criteria:

  • Subject has been diagnosed with JIA by a pediatric rheumatologist according to published criteria.
  • Person providing consent must be able to read English.
  • Subject (and/or parent/legal guardian) is able to provide informed consent and willing to comply with study procedures.

Exclusion Criteria:

  • Subject/ legal guardian is unwilling to provide consent, cannot read English, or does not meet published criteria for JIA.
  • Coexisting rheumatologic disorder
  • Diagnosis of fibromyalgia
  • Participation in a drug trial in the past 6 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01469897

United States, Nebraska
Children's Hospital & Medical Center
Omaha, Nebraska, United States, 68114
United States, Ohio
The Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Texas
Dell Childrens Medical Center of Central Texas
Austin, Texas, United States, 78723
Sponsors and Collaborators
The Cleveland Clinic
Principal Investigator: Andrew Zeft, MD Cleveland Clinic Children's Hospital

Responsible Party: Andrew Zeft, Director, Center for Pediatric Rheumatology, The Cleveland Clinic Identifier: NCT01469897     History of Changes
Other Study ID Numbers: CCF 11-291
First Posted: November 10, 2011    Key Record Dates
Last Update Posted: January 17, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Andrew Zeft, The Cleveland Clinic:
Juvenile Idiopathic Arthritis
Cost of Care
Quality of Life

Additional relevant MeSH terms:
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases